Business Context and Reporting Period
Company: Boston Scientific Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2008
Business Overview: Boston Scientific is a global developer and manufacturer of medical devices used in interventional medical specialties, including interventional cardiology, cardiac rhythm management, endoscopy, urology, and neuromodulation. The company is currently executing strategic initiatives to divest non-strategic businesses, reduce expenses, and restructure operations to align costs with revenues.
Key Financial Metrics
| Metric (in millions) | Q3 2008 | Q3 2007 | 9 Months 2008 | 9 Months 2007 |
|---|---|---|---|---|
| Net Sales | $1,978 | $2,048 | $6,048 | $6,204 |
| Gross Profit | $1,323 | $1,473 | $4,209 | $4,498 |
| Gross Margin | 66.9% | 71.9% | 69.6% | 72.5% |
| Operating Income (Loss) | $28 | $(147) | $912 | $416 |
| Net Income (Loss) | $(62) | $(272) | $358 | $(37) |
| Diluted EPS | $(0.04) | $(0.18) | $0.24 | $(0.02) |
| Cash from Operations (9mo) | $1,162 (vs $626 prior year) | |||
| Total Debt | $6,774 (Sep 30, 2008) vs $8,189 (Dec 31, 2007) | |||
| Cash & Equivalents | $1,734 (Sep 30, 2008) |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 3% year-over-year for both the quarter and the nine-month period. The decline was driven by lower sales of drug-eluting coronary stents (specifically the TAXUS system) due to increased competition and a shift in sales mix toward the lower-margin PROMUS system supplied by Abbott Laboratories.
- Profitability Improvement: Despite lower sales, the company reported a net loss of $62 million for Q3 2008, a significant improvement from the $272 million loss in Q3 2007. For the nine months ended September 30, 2008, the company returned to profitability with $358 million in net income compared to a $37 million loss in the prior year.
- Margin Compression: Gross profit margins declined from 71.9% to 66.9% in Q3 2008. This was primarily due to the sales mix shift toward the PROMUS stent (which has lower margins under the supply agreement with Abbott) and inventory charges related to FDA warning letters and free technology offerings.
- Expense Reduction: Selling, General, and Administrative (SG&A) expenses decreased 15% in Q3 2008, and R&D expenses decreased 7%, largely due to business divestitures and the ongoing restructuring plan initiated in late 2007.
Guidance, Outlook, and Material Events
Unusual Items and One-Time Charges
- Litigation Charge: A pre-tax charge of $334 million ($266 million after-tax) was recorded in Q3 2008 resulting from a federal court ruling in a patent infringement case brought by Johnson & Johnson regarding the NIR stent. The company accrued this amount and is appealing the damage award.
- Acquisition Milestone Gain: The company recorded a $250 million pre-tax gain in Q3 2008 upon receiving a milestone payment from Abbott Laboratories following FDA approval of the XIENCE V stent.
- Intangible Asset Impairment: A $155 million pre-tax charge was recorded in Q3 2008 due to reduced revenue forecasts for Peripheral Interventions and Urology assets.
- Divestitures: The company completed the sale of non-strategic businesses (Auditory, Cardiac Surgery, Vascular Surgery, Fluid Management, Venous Access, and TriVascular EVAR) in early 2008, generating approximately $1.3 billion in pre-tax proceeds.
Restructuring and Strategic Initiatives
The company is executing a plan to eliminate approximately 2,300 positions worldwide, with total expected pre-tax expenses of $425 million to $450 million. Cumulative costs incurred since the plan's inception in October 2007 totaled $304 million as of September 30, 2008. The company expects to realize the majority of the targeted $475 million to $525 million in annualized R&D and SG&A savings by the end of 2008.
Risks and Contingencies
- Legal Proceedings: Significant ongoing litigation includes the Johnson & Johnson patent case (pending appeal), Medtronic patent disputes, and product liability claims related to Guidant defibrillators and pacemakers (MDL settlement up to $240 million).
- Regulatory Compliance: The company received a corporate warning letter from the FDA in 2006 regarding quality system issues. While the FDA indicated substantial compliance in October 2008, the letter remains in place pending final remediation of Medical Device Report filing issues.
- Supply Chain: The company relies on Abbott Laboratories for the supply of PROMUS stent systems. Any production or capacity issues at Abbott could adversely affect Boston Scientific's ability to meet demand.
Key Facts for Investor Verification
- Johnson & Johnson Litigation Status: Verify the progress of the appeal regarding the $703 million damage award (of which $334 million was accrued) and the potential for further financial impact.
- Stent Market Share: Monitor the company's market share in the U.S. drug-eluting stent market, which declined to 45% in Q3 2008 from 56% in Q3 2007, and the impact of new competitive launches (Abbott XIENCE V, Medtronic Endeavor).
- Restructuring Execution: Track the realization of the targeted $475 million to $525 million in annualized expense savings and the timeline for completing the 2,300 position reduction.
- Debt Covenants: Confirm continued compliance with debt covenants, specifically the total debt to EBITDA ratio (currently 2.8 to 1.0, well below the 4.5 to 1.0 limit) and the EBITDA to interest expense ratio (4.9 to 1.0).
- Product Launches: Verify the successful launch and market adoption of the TAXUS Liberté stent (approved Oct 2008) and the future launch of the PROMUS Element stent to improve gross margins.